Regardless of the mechanism involved in affecting the response to ICBs, we believe that furthering our understanding of the molecular mechanisms involved in the regulation of PD‐1 and its ligand PD‐L1 can contribute to the design of more effective anti‐PD‐1/PD‐L1‐based therapies and bring substantial benefits to cancer patients. This evidence concerns the gene CD274 and cancer.